Ranolazine is a medication used primarily for the management of chronic angina (chest pain) in patients with coronary artery disease. It is often used in combination with other medications to improve exercise tolerance and reduce the frequency of angina attacks.
Ranolazine is used to:
| Brand Name | Ranolazine |
|---|---|
| Type | |
| Weight | |
| Generic | Ranolazine |
| Manufacturer | |
| Available in | English বাংলা |
Ranolazine works by inhibiting late sodium current in cardiac myocytes. This action reduces intracellular sodium and calcium overload, which helps to decrease myocardial oxygen demand and improve the heart's efficiency. Unlike many other anti-anginal agents, ranolazine does not significantly affect heart rate or blood pressure.
Ranolazine may start to provide symptomatic relief within 1-2 weeks of starting therapy, but it often takes up to 4-6 weeks to achieve its full therapeutic effect. Consistent use as prescribed is important for optimal results.
Ranolazine is well absorbed after oral administration, with peak plasma concentrations typically occurring within 2-4 hours. Its absorption can be influenced by food, and taking the drug with a high-fat meal may increase its absorption.
Ranolazine is primarily metabolized in the liver by the cytochrome P450 enzyme system, mainly CYP3A4. Its metabolites are excreted through the urine, with a small amount being eliminated via feces.
The usual dosage of Ranolazine is:
Ranolazine is administered orally in the form of extended-release tablets. It should be taken with or without food, but it is recommended to take it consistently with respect to meals to ensure stable blood levels.
Common side effects include:
Toxicity from Ranolazine is rare but can occur with overdose or excessive use. Symptoms may include severe dizziness, confusion, or abnormal heart rhythms. Seek immediate medical attention if an overdose is suspected.
Precautions include:
Ranolazine may interact with:
Use Ranolazine with caution in patients with:
Drug interactions can occur with:
There are no significant food interactions with Ranolazine , but taking the medication consistently with respect to food intake is recommended to maintain stable drug levels.
Ranolazine is classified as a Category C drug during pregnancy. This means that risk to the fetus cannot be ruled out. Use during pregnancy should be considered only if the potential benefits outweigh the risks, and only under the guidance of a healthcare provider.
The safety of Ranolazine during lactation is not well established. It is recommended to consult a healthcare provider before using Ranolazine while breastfeeding, as the drug may be excreted in breast milk.
In the event of acute overdose, symptoms may include severe dizziness, confusion, and potential cardiac arrhythmias. Immediate medical attention is required for appropriate treatment and management of overdose symptoms.
Ranolazine is contraindicated in:
Follow the prescribed dosage and administration instructions carefully. Take Ranolazine orally, twice daily, with or without food. Do not exceed the recommended dose and consult a healthcare provider for any dose adjustments or concerns.
Store Ranolazine tablets at room temperature, away from direct light and moisture. Keep out of reach of children and do not use past the expiration date.
The volume of distribution for Ranolazine is approximately 2-4 L/kg, indicating that it is distributed widely in body tissues.
The half-life of Ranolazine is approximately 7 hours, which supports its dosing schedule of twice daily administration.
Ranolazine is primarily cleared through hepatic metabolism, with renal excretion of its metabolites. The clearance rate can be influenced by liver function and the presence of interacting drugs.
See in details version Ranolazine also Ranolazine in bangla
Dr. Md. Fazle Bari
Medicine (All Diseases of Adults) Specialist
Medicine Specialist Doctor in Sylhet
Prof. Dr. AHM Mustafizur Rahman
Psychiatry (Mental Diseases) Specialist & Psychotherapist
Psychologist in Dhaka